Patents by Inventor Stephen Connolly

Stephen Connolly has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230069044
    Abstract: The present disclosure relates to certain (2S)—N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds (including pharmaceutically acceptable salts thereof), that inhibit dipeptidyl peptidase 1 (DPP1) activity, to their utility in treating and/or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds.
    Type: Application
    Filed: September 9, 2022
    Publication date: March 2, 2023
    Inventors: Hans Roland LÖNN, Stephen CONNOLLY, Steven SWALLOW, Staffan PO KARLSSON, Carl-Johan AURELL, John Fritiof PONTÉN, Kevin James DOYLE, Amanda Jane VAN DE POËL, Graham Peter JONES, David Wyn WATSON, Jaqueline Anne MACRITCHIE, Nicholas John PALMER
  • Publication number: 20230033573
    Abstract: The present disclosure relates to certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds (including pharmaceutically acceptable salts thereof), that inhibit dipeptidyl peptidase 1 (DPP1) activity, to their utility in treating and/or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD) , to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds.
    Type: Application
    Filed: September 10, 2022
    Publication date: February 2, 2023
    Inventors: Hans Roland LÖNN, Stephen CONNOLLY, Steven SWALLOW, Staffan PO KARLSSON, Carl-Johan AURELL, John Fritiof PONTÉN, Kevin James DOYLE, Amanda Jane VAN DE POËL, Graham Peter JONES, David Wyn WATSON, Jaqueline Anne MACRITCHIE, Nicholas John PALMER
  • Publication number: 20230028726
    Abstract: The present disclosure relates to certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds (including pharmaceutically acceptable salts thereof), that inhibit dipeptidyl peptidase 1 (DPP1) activity, to their utility in treating and/or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds.
    Type: Application
    Filed: September 10, 2022
    Publication date: January 26, 2023
    Inventors: Hans Roland LÖNN, Stephen CONNOLLY, Steven SWALLOW, Staffan PO KARLSSON, Carl-Johan AURELL, John Fritiof PONTÉN, Kevin James DOYLE, Amanda Jane VAN DE POËL, Graham Peter JONES, David Wyn WATSON, Jaqueline Anne MACRITCHIE, Nicholas John PALMER
  • Publication number: 20230025351
    Abstract: The present disclosure relates to certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds (including pharmaceutically acceptable salts thereof), that inhibit dipeptidyl peptidase 1 (DPP1) activity, to their utility in treating and/or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds.
    Type: Application
    Filed: September 10, 2022
    Publication date: January 26, 2023
    Inventors: Hans Roland LÖNN, Stephen CONNOLLY, Steven SWALLOW, Staffan PO KARLSSON, Carl-Johan AURELL, John Fritiof PONTÉN, Kevin James DOYLE, Amanda Jane VAN DE POËL, Graham Peter JONES, David Wyn WATSON, Jaqueline Anne MACRITCHIE, Nicholas John PALMER
  • Publication number: 20220133737
    Abstract: The present disclosure relates to methods for treating bronchiectasis, for example, non-cystic fibrosis bronchiectasis with compositions comprising an effective amount of certain (2S)—N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds of Formula (I), including pharmaceutically acceptable salts thereof, that inhibit dipeptidyl peptidase 1 (DPP1) activity. Methods provided herein are useful for prophylaxis, increasing the lung function in a patient, and/or and/or decreasing the rate of pulmonary exacerbation in a patient. In one embodiment, the compound of Formula (I) is (2S)—N-{(1S)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide.
    Type: Application
    Filed: January 14, 2022
    Publication date: May 5, 2022
    Inventors: Hans Roland LONN, Stephen CONNOLLY, Steven SWALLOW, Reinilde HEYRMAN, Eugene SULLIVAN, Carlos FERNANDEZ
  • Patent number: 11220483
    Abstract: Novel tetrahydroisoquinoline and tetrahydrobenzazepine compounds of formula (I) capable of modulating the G-protein-coupled receptor GPR120, compositions comprising the compounds, and methods for their use for controlling insulin levels in vivo and for the treatment of conditions such as of diabetes, inflammation, obesity and metabolic diseases.
    Type: Grant
    Filed: March 26, 2018
    Date of Patent: January 11, 2022
    Assignee: CALDAN THERAPEUTICS LTD
    Inventors: Jane Brown, Stephen Connolly, Steffen V. F. Hansen, Gavin Milne, Bharat Shimpukade, Don Smyth, Gerard Thomas, Trond Ulven, Matjaz Brvar, Aaron Rigby
  • Patent number: 11117874
    Abstract: The present disclosure relates to certain (2S)—N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds (including pharmaceutically acceptable salts thereof), that inhibit dipeptidyl peptidase 1 (DPP1) activity, to their utility in treating and/or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds.
    Type: Grant
    Filed: April 22, 2020
    Date of Patent: September 14, 2021
    Assignee: ASTRAZENECA AB
    Inventors: Hans Roland Lonn, Stephen Connolly, Steven Swallow, Staffan PO Karlsson, Carl-Johan Aurell, John Fritiof Pontén, Kevin James Doyle, Amanda Jane Van De Poël, Graham Peter Jones, David Wyn Watson, Jaqueline Anne Macritchie, Nicholas John Palmer
  • Publication number: 20210238152
    Abstract: The present disclosure relates to certain (2S)—N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds (including pharmaceutically acceptable salts thereof), that inhibit dipeptidyl peptidase 1 (DPP1) activity, to their utility in treating and/or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds.
    Type: Application
    Filed: February 8, 2021
    Publication date: August 5, 2021
    Inventors: Hans Roland LÖNN, Stephen CONNOLLY, Steven SWALLOW, Staffan PO KARLSSON, Carl-Johan AURELL, John Fritiof PONTÉN, Kevin James DOYLE, Amanda Jane VAN DE POËL, Graham Peter JONES, David Wyn WATSON, Jaqueline Anne MACRITCHIE, Nicholas John PALMER
  • Patent number: 10954211
    Abstract: The present invention provides a compound of a formula (I): or a pharmaceutically acceptable salt thereof; a process for preparing such a compound; and to the use of such a compound in the treatment of an ENaC mediated disease state (such as asthma, CF or COPD).
    Type: Grant
    Filed: May 10, 2019
    Date of Patent: March 23, 2021
    Assignee: ASTRAZENECA AB
    Inventors: Susanne Elisabeth Berglund, Stephen Connolly, Martin Hemmerling, Nafizal Hossain, Anna Kristoffersson, Johan Rune Michael Lundkvist, Grigorios Nikitidis, Lena Elisabeth Ripa, Igor Shamovsky
  • Publication number: 20200317619
    Abstract: Novel tetrahydroisoquinoline and tetrahydrobenzazepine compounds of formula (I) capable of modulating the G-protein-coupled receptor GPR120, compositions comprising the compounds, and methods for their use for controlling insulin levels in vivo and for the treatment of conditions such as of diabetes, inflammation, obesity and metabolic diseases.
    Type: Application
    Filed: March 26, 2018
    Publication date: October 8, 2020
    Inventors: Jane BROWN, Stephen CONNOLLY, Steffen V.F. HANSEN, Gavin MILNE, Bharat SHIMPUKADE, Don SMYTH, Gerard THOMAS, Trond ULVEN, Matjaz BRVAR, Aaron RIGBY
  • Publication number: 20200247765
    Abstract: The present disclosure relates to certain (2S)—N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds (including pharmaceutically acceptable salts thereof), that inhibit dipeptidyl peptidase 1 (DPP1) activity, to their utility in treating and/or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds.
    Type: Application
    Filed: April 22, 2020
    Publication date: August 6, 2020
    Inventors: Hans Roland LONN, Stephen CONNOLLY, Steven SWALLOW, Staffan PO KARLSSON, Carl-Johan AURELL, John Fritiof PONTÉN, Kevin James DOYLE, Amanda Jane VAN DE POËL, Graham Peter JONES, David Wyn WATSON, Jaqueline Anne MACRITCHIE, Nicholas John PALMER
  • Publication number: 20200179398
    Abstract: The present disclosure relates to methods for treating bronchiectasis, for example, non-cystic fibrosis bronchiectasis with compositions comprising an effective amount of certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds of Formula (I), including pharmaceutically acceptable salts thereof, that inhibit dipeptidyl peptidase 1 (DPP1) activity. Methods provided herein are useful for prophylaxis, increasing the lung function in a patient, and/or decreasing the rate of pulmonary exacerbation in a patient. In one embodiment, the compound of Formula (I) is (2S)-N-{(1S)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide.
    Type: Application
    Filed: July 15, 2019
    Publication date: June 11, 2020
    Inventors: Hans Roland LONN, Stephen CONNOLLY, Steven SWALLOW, Reinilde HEYRMAN, Eugene SULLIVAN, Carlos FERNANDEZ
  • Patent number: 10669245
    Abstract: The present disclosure relates to certain (2S)—N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds (including pharmaceutically acceptable salts thereof), that inhibit dipeptidyl peptidase 1 (DPP1) activity, to their utility in treating and/or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds.
    Type: Grant
    Filed: March 19, 2019
    Date of Patent: June 2, 2020
    Assignee: ASTRAZENECA AB
    Inventors: Hans Roland Lonn, Stephen Connolly, Steven Swallow, Staffan Po Karlsson, Carl-Johan Aurell, John Fritiof Pontén, Kevin James Doyle, Amanda Jane Van De Poël, Graham Peter Jones, David Wyn Watson, Jaqueline Anne Macritchie, Nicholas John Palmer
  • Publication number: 20200017455
    Abstract: The present disclosure relates to certain (2S)—N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds (including pharmaceutically acceptable salts thereof), that inhibit dipeptidyl peptidase 1 (DPP1) activity, to their utility in treating and/or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds.
    Type: Application
    Filed: March 19, 2019
    Publication date: January 16, 2020
    Inventors: Hans Roland LONN, Stephen CONNOLLY, Steven SWALLOW, Staffan PO KARLSSON, Carl-Johan AURELL, John Fritiof PONTÉN, Kevin James DOYLE, Amanda Jane VAN DE POËL, Graham Peter JONES, David Wyn WATSON, Jaqueline Anne MACRITCHIE, Nicholas John PALMER
  • Publication number: 20190330187
    Abstract: The present invention provides a compound of a formula (I): or a pharmaceutically acceptable salt thereof; a process for preparing such a compound; and to the use of such a compound in the treatment of an ENaC mediated disease state (such as asthma, CF or COPD).
    Type: Application
    Filed: May 10, 2019
    Publication date: October 31, 2019
    Inventors: Susanne Elisabeth BERGLUND, Stephen CONNOLLY, Martin HEMMERLING, Nafizal HOSSAIN, Anna KRISTOFFERSSON, Johan Rune Michael LUNDKVIST, Grigorios NIKITIDIS, Lena Elisabeth RIPA, Igor SHAMOVSKY
  • Patent number: 10336725
    Abstract: The present invention provides a compound of a formula (I): or a pharmaceutically acceptable salt thereof; a process for preparing such a compound; and to the use of such a compound in the treatment of an ENaC mediated disease state (such as asthma, CF or COPD).
    Type: Grant
    Filed: December 13, 2017
    Date of Patent: July 2, 2019
    Assignee: AstraZeneca AB
    Inventors: Susanne Elisabeth Berglund, Stephen Connolly, Martin Hemmerling, Nafizal Hossain, Anna Kristoffersson, Johan Rune Michael Lundkvist, Grigorios Nikitidis, Lena Elisabeth Ripa, Igor Shamovsky
  • Patent number: 10287258
    Abstract: The present disclosure relates to certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds (including pharmaceutically acceptable salts thereof), that inhibit dipeptidyl peptidase 1 (DPP1) activity, to their utility in treating and/or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds.
    Type: Grant
    Filed: September 19, 2017
    Date of Patent: May 14, 2019
    Assignee: ASTRAZENECA AB
    Inventors: Hans Roland Lonn, Stephen Connolly, Steven Swallow, Staffan Po Karlsson, Carl-Johan Aurell, John Fritiof Pontén, Kevin James Doyle, Amanda Jane Van De Poël, Graham Peter Jones, David Wyn Watson, Jaqueline Anne Macritchie, Nicholas John Palmer
  • Publication number: 20190091236
    Abstract: The present disclosure relates to methods for treating bronchiectasis, for example, non-cystic fibrosis bronchiectasis with compositions comprising an effective amount of certain (2S)—N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds of Formula (I), including pharmaceutically acceptable salts thereof, that inhibit dipeptidyl peptidase 1 (DPP1) activity. Methods provided herein are useful for prophylaxis, increasing the lung function in a patient, and/or and/or decreasing the rate of pulmonary exacerbation in a patient. In one embodiment, the compound of Formula (I) is (2S)—N-{(1S)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide.
    Type: Application
    Filed: November 21, 2018
    Publication date: March 28, 2019
    Applicants: AstraZeneca AB, Insmed Incorporated
    Inventors: Hans Roland Lonn, Stephen Connolly, Steven Swallow, Reinilde Heyrman, Eugene Sullivan, Carlos Fernandez
  • Publication number: 20180251436
    Abstract: The present disclosure relates to certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds (including pharmaceutically acceptable salts thereof), that inhibit dipeptidyl peptidase 1 (DPP1) activity, to their utility in treating and/or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds.
    Type: Application
    Filed: September 19, 2017
    Publication date: September 6, 2018
    Inventors: Hans Roland LONN, Stephen CONNOLLY, Steven SWALLOW, Staffan PO KARLSSON, Carl-Johan AURELL, John Fritiof PONTÉN, Kevin James DOYLE, Amanda Jane VAN DE POËL, Graham Peter JONES, David Wyn WATSON, Jaqueline Anne MACRITCHIE, Nicholas John PALMER
  • Publication number: 20180162838
    Abstract: The present invention provides a compound of a formula (I): or a pharmaceutically acceptable salt thereof; a process for preparing such a compound; and to the use of such a compound in the treatment of an ENaC mediated disease state (such as asthma, CF or COPD).
    Type: Application
    Filed: December 13, 2017
    Publication date: June 14, 2018
    Inventors: Susanne Elisabeth BERGLUND, Stephen CONNOLLY, Martin HEMMERLING, Nafizal HOSSAIN, Anna KRISTOFFERSSON, Johan Rune Michael LUNDKVIST, Grigorios NIKITIDIS, Lena Elisabeth RIPA, Igor SHAMOVSKY